Health Trials

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

ConditionPrimary Membranous Nephropathy
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorVertex Pharmaceuticals Incorporated

About this trial

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Povetacicept
  • Tacrolimus

Treatment groups

176 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Vertex Pharmaceuticals Incorporated

Lead sponsor

Zai Lab (Shanghai) Co., Ltd. (for China only)

Collaborator

Source ClinicalTrials.gov